No Data
No Data
Zura Bio (ZURA) Receives a Buy From Piper Sandler
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Cuts Target Price to $12
Optimistic Outlook on Zura Bio: Tibulizumab's Potential and Market Opportunity
Express News | Cantor Fitzgerald Reiterates Overweight on Zura Bioto Overweight
Express News | Zura Bio Ltd : Leerink Partners Cuts Target Price to $12 From $15
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference